Gene expression profile at single cell level of bone marrow cells in 5TGM1 multiple myeloma mouse model treated with CD24 CAR-T cells

Durable remissions following anti-B cell maturation antigen (BCMA)-specific chimeric antigen receptor (CAR) T-cell treatment of multiple myeloma (MM) are rare. Relapses occur when a small subset of MM tumor-initiating cells (TICs) survive treatment. MM cells expressing CD24 exhibit features of TICs. We developed CD24-CAR-T cells and tested their ability to eliminate MM TICs in vitro and in vivo. Overall design: We analyzed the immune cell changes in the BM microenvironment of the 5TGM1 mouse model treated with CD24 CAR-T cells using single-cell RNA sequencing (scRNA-seq).